Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
Mukhopadhyay P, Horváth B, Rajesh M, Varga ZV, Gariani K, Ryu D, Cao Z, Holovac E, Park O, Zhou Z, Xu MJ, Wang W, Godlewski G, Paloczi J, Nemeth BT, Persidsky Y, Liaudet L, Haskó G, Bai P, Boulares AH, Auwerx J, Gao B, Pacher P. Mukhopadhyay P, et al. Among authors: boulares ah. J Hepatol. 2017 Mar;66(3):589-600. doi: 10.1016/j.jhep.2016.10.023. Epub 2016 Oct 29. J Hepatol. 2017. PMID: 27984176
Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis.
Mukhopadhyay P, Rajesh M, Cao Z, Horváth B, Park O, Wang H, Erdelyi K, Holovac E, Wang Y, Liaudet L, Hamdaoui N, Lafdil F, Haskó G, Szabo C, Boulares AH, Gao B, Pacher P. Mukhopadhyay P, et al. Among authors: boulares ah. Hepatology. 2014 May;59(5):1998-2009. doi: 10.1002/hep.26763. Epub 2014 Apr 1. Hepatology. 2014. PMID: 24089324 Free PMC article.
PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.
Ghonim MA, Pyakurel K, Ibba SV, Wang J, Rodriguez P, Al-Khami AA, Lammi MR, Kim H, Zea AH, Davis C, Okpechi S, Wyczechowska D, Al-Ghareeb K, Mansy MS, Ochoa A, Naura AS, Boulares AH. Ghonim MA, et al. Among authors: boulares ah. Clin Sci (Lond). 2015 Dec;129(11):951-62. doi: 10.1042/CS20150122. Epub 2015 Jul 23. Clin Sci (Lond). 2015. PMID: 26205779 Free PMC article.
Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.
Berger NA, Besson VC, Boulares AH, Bürkle A, Chiarugi A, Clark RS, Curtin NJ, Cuzzocrea S, Dawson TM, Dawson VL, Haskó G, Liaudet L, Moroni F, Pacher P, Radermacher P, Salzman AL, Snyder SH, Soriano FG, Strosznajder RP, Sümegi B, Swanson RA, Szabo C. Berger NA, et al. Among authors: boulares ah. Br J Pharmacol. 2018 Jan;175(2):192-222. doi: 10.1111/bph.13748. Epub 2017 Mar 26. Br J Pharmacol. 2018. PMID: 28213892 Free PMC article. Review.
Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
Ghonim MA, Ibba SV, Tarhuni AF, Errami Y, Luu HH, Dean MJ, El-Bahrawy AH, Wyczechowska D, Benslimane IA, Del Valle L, Al-Khami AA, Ochoa AC, Boulares AH. Ghonim MA, et al. Among authors: boulares ah. J Immunother Cancer. 2021 Jan;9(1):e001643. doi: 10.1136/jitc-2020-001643. J Immunother Cancer. 2021. PMID: 33495297 Free PMC article.
72 results